Explore 3 Stock Ideas & Industry Insights Download Free Report

News

AAON Director Purchases 1,000 Shares at $74.66

A Form 4 filed with the SEC on September 16, 2026, discloses that David Raymond Stewart, a director of AAON, Inc. (NASDAQ:AAON), purchased 1,000 shares of common stock on September 15, 2026, at a price of $74.66 per share.

Aakashdeep | 16 September 2026

German American Bancorp Director Acquires Shares via Dividend Reinvestment Plan

Director Zachary W. Bawel filed a Form 4 with the SEC on September 16, 2026, disclosing a purchase of common stock in German American Bancorp, Inc. (NASDAQ:GABC) on September 15, 2026, through the company's Dividend Reinvestment and Stock Purchase Plan.

Manish Choudhary | 16 September 2026

German American Bancorp Director Buys Shares via DRIP

A Form 4 filed on September 16, 2026 reports that Christina M. Ryan, a director of German American Bancorp, Inc. (NASDAQ:GABC), acquired 124.2654 shares of common stock on September 15, 2026 through the company's Dividend Reinvestment and Stock Purchase Plan.

Anjali Anand | 16 September 2026

4D Molecular Therapeutics CEO Sells 58,333 Shares

David Kirn, President and Chief Executive Officer of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), filed a Form 4 on September 16, 2026, disclosing the sale of 58,333 shares of common stock on September 14, 2026.

Vinay Lochav | 16 September 2026

Alamar Biosciences General Counsel Receives RSUs and Stock Options

John L. Brottem, General Counsel of Alamar Biosciences, Inc. (NASDAQ:ALMR), filed a Form 4 on September 16, 2026, reporting the acquisition of 29,000 restricted stock units and an employee stock option covering 85,000 shares of common stock, both transacted on September 14, 2026.

Aditi Sarkar | 16 September 2026

Gilead Sciences Officer Sells 3,000 Shares in September 2026

Johanna Mercier, Chief Commercial and Corporate Affairs Officer at Gilead Sciences, Inc. (NASDAQ:GILD), filed a Form 4 on September 16, 2026, disclosing the sale of 3,000 shares of common stock on September 15, 2026, pursuant to a Rule 10b5-1 trading plan.

Vinay Lochav | 16 September 2026

Gilead Sciences CFO Sells 3,000 Shares Under 10b5-1 Plan

Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc., filed a Form 4 on September 16, 2026, reporting the sale of 3,000 shares of Gilead common stock on September 15, 2026.

Nitish Kishor | 16 September 2026

Stride Inc. General Counsel Reports Share Withholding

Stride, Inc. (NYSE:LRN) Executive Vice President and General Counsel Greerson Greene McMullen filed a statement of changes in beneficial ownership on September 16, 2026, disclosing a share disposition on September 15, 2026.

Manish Choudhary | 16 September 2026

Kayne Anderson BDC Director Buys 400,000 Shares

A Form 4 filed on September 16, 2026 with the U.S. Securities and Exchange Commission reported that James L. Robo, a director of Kayne Anderson BDC, Inc. (NYSE:KBDC), acquired a total of 400,000 shares of common stock through two purchases on September 14 and …

Nitish Kishor | 16 September 2026

Corcept Therapeutics Director Sells Shares Under 10b5-1 Plan

Director James N. Wilson filed a Form 4 with the SEC on September 16, 2026, reporting the sale of 10,000 shares of Corcept Therapeutics Inc common stock on September 15, 2026, executed under a pre-established 10b5-1 trading plan.

Shwetambri Chauhan | 16 September 2026
Support

Hi! How can we help you today?

Loading…